| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cocaine-Related Disorders | 100 | 2022 | 206 | 15.690 |
Why?
|
| Opioid-Related Disorders | 127 | 2025 | 285 | 14.660 |
Why?
|
| Substance-Related Disorders | 130 | 2024 | 483 | 13.600 |
Why?
|
| Schizophrenia | 91 | 2024 | 323 | 13.120 |
Why?
|
| Cocaine | 117 | 2022 | 207 | 11.920 |
Why?
|
| Buprenorphine | 58 | 2023 | 106 | 8.890 |
Why?
|
| Narcotic Antagonists | 47 | 2022 | 110 | 7.220 |
Why?
|
| Substance Withdrawal Syndrome | 76 | 2022 | 148 | 6.840 |
Why?
|
| Vaccines | 29 | 2024 | 379 | 6.500 |
Why?
|
| Methadone | 84 | 2022 | 126 | 6.050 |
Why?
|
| Schizophrenic Psychology | 29 | 2021 | 81 | 5.490 |
Why?
|
| Smoking | 30 | 2024 | 894 | 4.360 |
Why?
|
| Antipsychotic Agents | 41 | 2023 | 373 | 4.230 |
Why?
|
| Alcoholism | 35 | 2024 | 240 | 3.640 |
Why?
|
| Behavior, Addictive | 16 | 2021 | 59 | 3.570 |
Why?
|
| Cognition Disorders | 20 | 2020 | 542 | 3.390 |
Why?
|
| Double-Blind Method | 103 | 2025 | 1587 | 3.240 |
Why?
|
| Brain-Derived Neurotrophic Factor | 16 | 2015 | 98 | 3.140 |
Why?
|
| Analgesics, Opioid | 21 | 2023 | 447 | 2.890 |
Why?
|
| Adult | 325 | 2025 | 30189 | 2.780 |
Why?
|
| Naltrexone | 35 | 2022 | 68 | 2.760 |
Why?
|
| Narcotics | 34 | 2022 | 56 | 2.700 |
Why?
|
| Superoxide Dismutase | 8 | 2024 | 170 | 2.560 |
Why?
|
| Heroin Dependence | 35 | 2015 | 57 | 2.550 |
Why?
|
| Smoking Cessation | 22 | 2024 | 181 | 2.540 |
Why?
|
| Humans | 509 | 2025 | 125613 | 2.430 |
Why?
|
| Immunotherapy | 12 | 2024 | 727 | 2.420 |
Why?
|
| Dopamine beta-Hydroxylase | 11 | 2018 | 29 | 2.380 |
Why?
|
| Naloxone | 21 | 2018 | 46 | 2.330 |
Why?
|
| Stress Disorders, Post-Traumatic | 21 | 2025 | 646 | 2.230 |
Why?
|
| Male | 361 | 2025 | 61966 | 2.170 |
Why?
|
| Amphetamine-Related Disorders | 10 | 2019 | 37 | 2.080 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 8 | 2024 | 25 | 2.050 |
Why?
|
| Middle Aged | 179 | 2025 | 27263 | 2.000 |
Why?
|
| Disulfiram | 18 | 2022 | 33 | 1.940 |
Why?
|
| Psychiatric Status Rating Scales | 58 | 2023 | 822 | 1.870 |
Why?
|
| Methamphetamine | 8 | 2021 | 47 | 1.820 |
Why?
|
| Polymorphism, Genetic | 19 | 2020 | 788 | 1.800 |
Why?
|
| Female | 313 | 2025 | 67790 | 1.770 |
Why?
|
| Tobacco Use Disorder | 13 | 2020 | 88 | 1.700 |
Why?
|
| Fentanyl | 3 | 2024 | 53 | 1.690 |
Why?
|
| Brain | 35 | 2022 | 3016 | 1.660 |
Why?
|
| Bipolar Disorder | 13 | 2024 | 354 | 1.570 |
Why?
|
| Nicotine | 9 | 2023 | 108 | 1.570 |
Why?
|
| Depressive Disorder, Major | 7 | 2025 | 424 | 1.560 |
Why?
|
| Central Nervous System Stimulants | 13 | 2016 | 123 | 1.550 |
Why?
|
| Desipramine | 16 | 2005 | 26 | 1.540 |
Why?
|
| Mental Disorders | 18 | 2025 | 853 | 1.500 |
Why?
|
| China | 27 | 2024 | 273 | 1.440 |
Why?
|
| Treatment Outcome | 72 | 2025 | 12334 | 1.310 |
Why?
|
| Sex Characteristics | 11 | 2012 | 305 | 1.300 |
Why?
|
| Opiate Substitution Treatment | 5 | 2023 | 38 | 1.300 |
Why?
|
| Dopamine Uptake Inhibitors | 13 | 2018 | 33 | 1.290 |
Why?
|
| Plant Extracts | 4 | 2024 | 131 | 1.260 |
Why?
|
| Neuropsychological Tests | 27 | 2021 | 948 | 1.240 |
Why?
|
| Suicide | 3 | 2024 | 201 | 1.230 |
Why?
|
| Drug Therapy, Combination | 27 | 2024 | 1145 | 1.230 |
Why?
|
| Dyskinesia, Drug-Induced | 7 | 2013 | 44 | 1.220 |
Why?
|
| Clinical Trials as Topic | 30 | 2023 | 1103 | 1.210 |
Why?
|
| Oxidative Stress | 9 | 2013 | 752 | 1.160 |
Why?
|
| Genotype | 35 | 2024 | 2597 | 1.150 |
Why?
|
| Polymorphism, Single Nucleotide | 19 | 2016 | 2742 | 1.110 |
Why?
|
| Cross-Over Studies | 9 | 2024 | 323 | 1.090 |
Why?
|
| Heroin | 9 | 2022 | 19 | 1.090 |
Why?
|
| Comorbidity | 29 | 2024 | 1521 | 1.010 |
Why?
|
| Cues | 12 | 2017 | 97 | 1.000 |
Why?
|
| Cognition | 9 | 2024 | 781 | 0.990 |
Why?
|
| Young Adult | 51 | 2025 | 9556 | 0.990 |
Why?
|
| Dose-Response Relationship, Drug | 38 | 2016 | 1596 | 0.980 |
Why?
|
| Ginkgo biloba | 3 | 2024 | 11 | 0.970 |
Why?
|
| Bupropion | 10 | 2024 | 26 | 0.960 |
Why?
|
| Behavior Therapy | 9 | 2009 | 263 | 0.950 |
Why?
|
| Movement Disorders | 9 | 2013 | 221 | 0.930 |
Why?
|
| Analysis of Variance | 26 | 2017 | 949 | 0.930 |
Why?
|
| Chronic Disease | 23 | 2013 | 1176 | 0.900 |
Why?
|
| Pharmacogenetics | 12 | 2023 | 196 | 0.890 |
Why?
|
| Veterans | 12 | 2024 | 1726 | 0.890 |
Why?
|
| Antibodies | 12 | 2015 | 350 | 0.880 |
Why?
|
| Depressive Disorder | 31 | 2016 | 459 | 0.870 |
Why?
|
| Clonidine | 9 | 2019 | 29 | 0.850 |
Why?
|
| Dexmedetomidine | 1 | 2024 | 47 | 0.840 |
Why?
|
| Acupuncture Therapy | 5 | 2014 | 10 | 0.840 |
Why?
|
| Analgesics | 3 | 2013 | 119 | 0.830 |
Why?
|
| Tardive Dyskinesia | 1 | 2024 | 13 | 0.830 |
Why?
|
| Nipecotic Acids | 5 | 2006 | 9 | 0.820 |
Why?
|
| Doxazosin | 3 | 2020 | 27 | 0.810 |
Why?
|
| Nicotinic Agonists | 5 | 2024 | 32 | 0.810 |
Why?
|
| Cerebrovascular Circulation | 10 | 2005 | 448 | 0.810 |
Why?
|
| Clozapine | 7 | 2011 | 26 | 0.800 |
Why?
|
| Cholera Toxin | 2 | 2013 | 43 | 0.790 |
Why?
|
| Substance Abuse Detection | 18 | 2015 | 40 | 0.790 |
Why?
|
| Depression | 13 | 2022 | 1283 | 0.780 |
Why?
|
| Dopamine Agonists | 5 | 2015 | 55 | 0.780 |
Why?
|
| Marijuana Abuse | 4 | 2019 | 53 | 0.770 |
Why?
|
| Genetic Predisposition to Disease | 24 | 2024 | 3248 | 0.770 |
Why?
|
| Ambulatory Care | 13 | 2018 | 387 | 0.750 |
Why?
|
| Case-Control Studies | 28 | 2023 | 3295 | 0.750 |
Why?
|
| Prescription Drugs | 2 | 2014 | 50 | 0.750 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 10 | 2021 | 225 | 0.750 |
Why?
|
| Weight Gain | 5 | 2023 | 375 | 0.740 |
Why?
|
| Antidepressive Agents, Tricyclic | 4 | 2003 | 28 | 0.740 |
Why?
|
| Risperidone | 6 | 2019 | 61 | 0.730 |
Why?
|
| Drugs, Chinese Herbal | 2 | 2014 | 22 | 0.730 |
Why?
|
| Suicidal Ideation | 5 | 2025 | 248 | 0.720 |
Why?
|
| Tetanus Toxoid | 2 | 2019 | 48 | 0.720 |
Why?
|
| Thioredoxins | 2 | 2012 | 23 | 0.700 |
Why?
|
| Guanfacine | 3 | 2019 | 7 | 0.700 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 3 | 2020 | 18 | 0.690 |
Why?
|
| Blood Pressure | 27 | 2021 | 1302 | 0.690 |
Why?
|
| Methionine | 6 | 2012 | 89 | 0.690 |
Why?
|
| Valine | 6 | 2012 | 105 | 0.690 |
Why?
|
| Hippocampus | 7 | 2021 | 772 | 0.680 |
Why?
|
| Heart Rate | 23 | 2017 | 563 | 0.680 |
Why?
|
| Vaccination | 7 | 2015 | 994 | 0.670 |
Why?
|
| Suicide, Attempted | 4 | 2025 | 151 | 0.670 |
Why?
|
| Psychotic Disorders | 4 | 2019 | 150 | 0.670 |
Why?
|
| Cognitive Dysfunction | 5 | 2025 | 281 | 0.670 |
Why?
|
| Hydrocortisone | 23 | 2009 | 221 | 0.670 |
Why?
|
| Secondary Prevention | 8 | 2019 | 214 | 0.660 |
Why?
|
| Animals | 50 | 2025 | 33094 | 0.650 |
Why?
|
| Combined Modality Therapy | 25 | 2024 | 1228 | 0.650 |
Why?
|
| Ketamine | 2 | 2023 | 222 | 0.640 |
Why?
|
| Sertraline | 4 | 2022 | 44 | 0.640 |
Why?
|
| Aluminum Hydroxide | 2 | 2019 | 38 | 0.630 |
Why?
|
| Arousal | 12 | 2006 | 77 | 0.620 |
Why?
|
| Sex Factors | 20 | 2025 | 1292 | 0.610 |
Why?
|
| Immunotherapy, Active | 2 | 2009 | 18 | 0.610 |
Why?
|
| Stress, Psychological | 6 | 2020 | 545 | 0.610 |
Why?
|
| Toll-Like Receptor 5 | 1 | 2019 | 7 | 0.610 |
Why?
|
| Aged | 43 | 2024 | 19970 | 0.600 |
Why?
|
| Interleukin-18 | 3 | 2016 | 64 | 0.600 |
Why?
|
| Neuroimmunomodulation | 1 | 2019 | 14 | 0.600 |
Why?
|
| Alcohol Deterrents | 5 | 2013 | 12 | 0.600 |
Why?
|
| Morphine | 4 | 2014 | 75 | 0.590 |
Why?
|
| Headache | 2 | 2021 | 95 | 0.590 |
Why?
|
| Dopamine | 14 | 2014 | 247 | 0.590 |
Why?
|
| GABA Agents | 4 | 2011 | 20 | 0.590 |
Why?
|
| Memory Disorders | 3 | 2021 | 205 | 0.580 |
Why?
|
| Hydrolases | 3 | 2013 | 59 | 0.580 |
Why?
|
| Phospholipids | 1 | 2019 | 99 | 0.570 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 14 | 2004 | 97 | 0.570 |
Why?
|
| Receptors, Opioid, kappa | 3 | 2019 | 23 | 0.570 |
Why?
|
| Antioxidants | 5 | 2013 | 318 | 0.560 |
Why?
|
| Inpatients | 7 | 2025 | 538 | 0.560 |
Why?
|
| Ethanol | 6 | 2025 | 158 | 0.550 |
Why?
|
| gamma-Aminobutyric Acid | 7 | 2016 | 164 | 0.550 |
Why?
|
| Cerebral Cortex | 7 | 2022 | 442 | 0.550 |
Why?
|
| Substance Abuse, Intravenous | 8 | 1998 | 43 | 0.550 |
Why?
|
| Brain Injuries, Traumatic | 2 | 2018 | 282 | 0.540 |
Why?
|
| Drug Administration Schedule | 19 | 2019 | 734 | 0.530 |
Why?
|
| Delayed-Action Preparations | 7 | 2022 | 117 | 0.530 |
Why?
|
| Severity of Illness Index | 21 | 2014 | 2917 | 0.520 |
Why?
|
| Adrenergic Uptake Inhibitors | 2 | 2009 | 29 | 0.520 |
Why?
|
| Adolescent | 42 | 2025 | 19904 | 0.510 |
Why?
|
| Psychomotor Performance | 7 | 2013 | 174 | 0.510 |
Why?
|
| Drug Discovery | 2 | 2017 | 169 | 0.510 |
Why?
|
| Cost of Illness | 1 | 2019 | 282 | 0.510 |
Why?
|
| Pilot Projects | 17 | 2021 | 1380 | 0.510 |
Why?
|
| Tumor Necrosis Factor-alpha | 6 | 2019 | 638 | 0.500 |
Why?
|
| Placebos | 15 | 2011 | 221 | 0.500 |
Why?
|
| Legislation, Medical | 1 | 2016 | 13 | 0.500 |
Why?
|
| Sequence Deletion | 3 | 2013 | 508 | 0.490 |
Why?
|
| Gene Frequency | 15 | 2016 | 739 | 0.490 |
Why?
|
| Drug Prescriptions | 2 | 2016 | 222 | 0.490 |
Why?
|
| Affect | 11 | 2019 | 166 | 0.480 |
Why?
|
| Alleles | 16 | 2021 | 1606 | 0.480 |
Why?
|
| Rats | 18 | 2022 | 3388 | 0.480 |
Why?
|
| Receptors, Dopamine D3 | 1 | 2015 | 8 | 0.470 |
Why?
|
| Benzothiazoles | 1 | 2015 | 29 | 0.470 |
Why?
|
| Motivation | 8 | 2015 | 323 | 0.470 |
Why?
|
| Haloperidol | 3 | 2013 | 20 | 0.470 |
Why?
|
| Antidepressive Agents | 5 | 2024 | 313 | 0.470 |
Why?
|
| Drug Therapy | 3 | 2022 | 84 | 0.470 |
Why?
|
| Alcohol-Related Disorders | 4 | 2007 | 34 | 0.460 |
Why?
|
| Cannabinoids | 3 | 2019 | 32 | 0.460 |
Why?
|
| Fluoxetine | 2 | 2014 | 43 | 0.460 |
Why?
|
| Office Visits | 4 | 2007 | 78 | 0.450 |
Why?
|
| Dextroamphetamine | 2 | 2009 | 6 | 0.450 |
Why?
|
| Immunoglobulin G | 3 | 2013 | 751 | 0.440 |
Why?
|
| Transcranial Direct Current Stimulation | 2 | 2024 | 22 | 0.440 |
Why?
|
| Anxiety | 11 | 2024 | 961 | 0.440 |
Why?
|
| Habenula | 3 | 2020 | 44 | 0.440 |
Why?
|
| Gyrus Cinguli | 5 | 2020 | 125 | 0.440 |
Why?
|
| Drug Design | 2 | 2014 | 153 | 0.440 |
Why?
|
| Interleukin-6 | 4 | 2019 | 404 | 0.440 |
Why?
|
| Temperance | 4 | 2013 | 15 | 0.430 |
Why?
|
| Cross-Sectional Studies | 18 | 2024 | 3645 | 0.430 |
Why?
|
| Norepinephrine | 10 | 2018 | 152 | 0.430 |
Why?
|
| Sensory Gating | 2 | 2020 | 13 | 0.430 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2023 | 1178 | 0.420 |
Why?
|
| Progesterone | 2 | 2007 | 431 | 0.420 |
Why?
|
| Transcranial Magnetic Stimulation | 2 | 2024 | 76 | 0.420 |
Why?
|
| Interleukin-2 | 4 | 2015 | 231 | 0.420 |
Why?
|
| Psychiatry | 6 | 2016 | 270 | 0.410 |
Why?
|
| Cross-Cultural Comparison | 3 | 2010 | 57 | 0.400 |
Why?
|
| Akathisia, Drug-Induced | 2 | 2010 | 12 | 0.400 |
Why?
|
| Membrane Transport Proteins | 6 | 2000 | 171 | 0.400 |
Why?
|
| Pain | 2 | 2018 | 429 | 0.400 |
Why?
|
| Cholera Vaccines | 1 | 2013 | 7 | 0.400 |
Why?
|
| Dopamine Agents | 4 | 2013 | 29 | 0.400 |
Why?
|
| Chi-Square Distribution | 10 | 2013 | 541 | 0.400 |
Why?
|
| Regression Analysis | 10 | 2012 | 760 | 0.400 |
Why?
|
| GABA Agonists | 4 | 2014 | 15 | 0.400 |
Why?
|
| S100 Proteins | 2 | 2009 | 41 | 0.390 |
Why?
|
| HIV Seropositivity | 4 | 1998 | 124 | 0.390 |
Why?
|
| Time Factors | 25 | 2015 | 6020 | 0.390 |
Why?
|
| Methadyl Acetate | 3 | 2005 | 3 | 0.390 |
Why?
|
| Acupuncture Points | 4 | 2000 | 4 | 0.390 |
Why?
|
| Nerve Growth Factors | 2 | 2009 | 70 | 0.390 |
Why?
|
| Auditory Perceptual Disorders | 1 | 2012 | 5 | 0.390 |
Why?
|
| Antibody Specificity | 1 | 2013 | 196 | 0.380 |
Why?
|
| Attitude of Health Personnel | 4 | 2021 | 687 | 0.380 |
Why?
|
| Psychotropic Drugs | 3 | 2007 | 122 | 0.380 |
Why?
|
| Nerve Tissue Proteins | 7 | 2017 | 1075 | 0.380 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 8 | 2019 | 34 | 0.380 |
Why?
|
| Reaction Time | 2 | 2017 | 157 | 0.380 |
Why?
|
| Immunoglobulin M | 1 | 2013 | 207 | 0.370 |
Why?
|
| Gene Transfer Techniques | 2 | 2013 | 332 | 0.370 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 376 | 0.370 |
Why?
|
| Vasodilator Agents | 2 | 2005 | 190 | 0.370 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 6 | 2015 | 23 | 0.370 |
Why?
|
| Impulsive Behavior | 3 | 2024 | 161 | 0.370 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 10 | 2014 | 780 | 0.360 |
Why?
|
| Maze Learning | 2 | 2011 | 101 | 0.360 |
Why?
|
| Receptors, Opioid, mu | 4 | 2018 | 31 | 0.360 |
Why?
|
| Alcohol Drinking | 4 | 2022 | 336 | 0.360 |
Why?
|
| Cerebrovascular Disorders | 2 | 2002 | 110 | 0.350 |
Why?
|
| Indoles | 1 | 2012 | 195 | 0.350 |
Why?
|
| Receptors, AMPA | 1 | 2011 | 36 | 0.350 |
Why?
|
| Anticonvulsants | 3 | 2005 | 375 | 0.350 |
Why?
|
| Prevalence | 11 | 2022 | 2558 | 0.350 |
Why?
|
| Risk Factors | 19 | 2025 | 10346 | 0.340 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 2 | 2020 | 7 | 0.340 |
Why?
|
| Acetaldehyde Dehydrogenase Inhibitors | 2 | 2022 | 5 | 0.340 |
Why?
|
| Single-Blind Method | 11 | 2019 | 229 | 0.340 |
Why?
|
| Smoking Prevention | 5 | 2012 | 33 | 0.340 |
Why?
|
| Psychoses, Substance-Induced | 2 | 2018 | 9 | 0.340 |
Why?
|
| Glutathione Peroxidase | 2 | 2007 | 46 | 0.330 |
Why?
|
| Dronabinol | 3 | 2019 | 30 | 0.330 |
Why?
|
| Catalase | 2 | 2007 | 63 | 0.330 |
Why?
|
| Nerve Net | 3 | 2019 | 245 | 0.330 |
Why?
|
| Surveys and Questionnaires | 15 | 2021 | 3884 | 0.320 |
Why?
|
| Decision Making | 2 | 2015 | 665 | 0.320 |
Why?
|
| Magnetic Resonance Imaging | 17 | 2022 | 3557 | 0.310 |
Why?
|
| United States | 19 | 2024 | 11141 | 0.310 |
Why?
|
| Drug Evaluation, Preclinical | 4 | 2017 | 149 | 0.310 |
Why?
|
| Gray Matter | 2 | 2022 | 44 | 0.300 |
Why?
|
| Acupuncture | 1 | 2009 | 1 | 0.300 |
Why?
|
| Medicine, Chinese Traditional | 1 | 2009 | 2 | 0.300 |
Why?
|
| Quality of Health Care | 2 | 2010 | 386 | 0.300 |
Why?
|
| Herbal Medicine | 1 | 2009 | 4 | 0.300 |
Why?
|
| Follow-Up Studies | 25 | 2013 | 5079 | 0.300 |
Why?
|
| Propylamines | 1 | 2009 | 8 | 0.300 |
Why?
|
| Genome-Wide Association Study | 4 | 2025 | 1715 | 0.300 |
Why?
|
| Antibodies, Monoclonal | 2 | 2013 | 988 | 0.300 |
Why?
|
| Antidepressive Agents, Second-Generation | 3 | 2008 | 33 | 0.300 |
Why?
|
| Nitric Oxide | 1 | 2011 | 461 | 0.290 |
Why?
|
| Psychosurgery | 1 | 2009 | 27 | 0.290 |
Why?
|
| Minocycline | 2 | 2019 | 42 | 0.290 |
Why?
|
| Neural Inhibition | 2 | 2016 | 104 | 0.290 |
Why?
|
| Isradipine | 3 | 2004 | 7 | 0.290 |
Why?
|
| Age Factors | 10 | 2013 | 2757 | 0.290 |
Why?
|
| Adjuvants, Immunologic | 4 | 2019 | 377 | 0.290 |
Why?
|
| Stereotaxic Techniques | 1 | 2009 | 75 | 0.290 |
Why?
|
| Psychotherapy | 8 | 2020 | 241 | 0.290 |
Why?
|
| Crack Cocaine | 2 | 2005 | 5 | 0.290 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 2 | 2020 | 16 | 0.290 |
Why?
|
| Triazines | 2 | 1998 | 31 | 0.290 |
Why?
|
| Lipid Peroxidation | 2 | 2013 | 89 | 0.290 |
Why?
|
| Benzodiazepines | 5 | 2003 | 106 | 0.280 |
Why?
|
| Vaccines, Conjugate | 3 | 2014 | 82 | 0.280 |
Why?
|
| Membrane Glycoproteins | 6 | 2000 | 406 | 0.280 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2019 | 74 | 0.280 |
Why?
|
| Age of Onset | 4 | 2013 | 607 | 0.280 |
Why?
|
| HIV Infections | 5 | 2008 | 1955 | 0.280 |
Why?
|
| Epigenesis, Genetic | 2 | 2012 | 710 | 0.270 |
Why?
|
| Amiloride | 2 | 2003 | 24 | 0.270 |
Why?
|
| Interleukins | 1 | 2008 | 119 | 0.270 |
Why?
|
| Leptin | 3 | 2009 | 218 | 0.270 |
Why?
|
| Progestins | 1 | 2007 | 43 | 0.270 |
Why?
|
| Yohimbine | 5 | 2002 | 13 | 0.270 |
Why?
|
| Mazindol | 4 | 1998 | 5 | 0.270 |
Why?
|
| Quality of Life | 2 | 2023 | 2007 | 0.270 |
Why?
|
| Connectome | 2 | 2020 | 97 | 0.260 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2019 | 1350 | 0.260 |
Why?
|
| Injections, Intramuscular | 3 | 2022 | 181 | 0.260 |
Why?
|
| Medication Adherence | 2 | 2014 | 331 | 0.260 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2016 | 15 | 0.260 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 2025 | 130 | 0.260 |
Why?
|
| beta-Endorphin | 7 | 2010 | 11 | 0.260 |
Why?
|
| Signal Detection, Psychological | 1 | 2007 | 10 | 0.260 |
Why?
|
| Self-Assessment | 4 | 2014 | 58 | 0.260 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2016 | 26 | 0.260 |
Why?
|
| Patient Compliance | 8 | 2019 | 460 | 0.260 |
Why?
|
| Everolimus | 1 | 2016 | 48 | 0.250 |
Why?
|
| Genetic Association Studies | 8 | 2013 | 806 | 0.250 |
Why?
|
| Hydromorphone | 2 | 1998 | 12 | 0.250 |
Why?
|
| Catechol O-Methyltransferase | 3 | 2012 | 29 | 0.250 |
Why?
|
| Piperidines | 2 | 2015 | 214 | 0.250 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 5 | 2013 | 47 | 0.250 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2010 | 681 | 0.250 |
Why?
|
| Carrier Proteins | 7 | 2012 | 1011 | 0.240 |
Why?
|
| Discrimination Learning | 4 | 2004 | 21 | 0.240 |
Why?
|
| Databases, Pharmaceutical | 1 | 2025 | 6 | 0.240 |
Why?
|
| Drug Repositioning | 1 | 2025 | 27 | 0.240 |
Why?
|
| Drug Interactions | 8 | 2009 | 238 | 0.240 |
Why?
|
| Hemocyanins | 3 | 2014 | 24 | 0.240 |
Why?
|
| Demography | 4 | 2013 | 235 | 0.240 |
Why?
|
| Brain Mapping | 6 | 2020 | 383 | 0.230 |
Why?
|
| Neurologic Examination | 10 | 1998 | 191 | 0.230 |
Why?
|
| Fructose | 1 | 2006 | 59 | 0.230 |
Why?
|
| Dextromethorphan | 3 | 2023 | 10 | 0.230 |
Why?
|
| Nitrates | 1 | 2025 | 32 | 0.230 |
Why?
|
| Marijuana Use | 1 | 2025 | 14 | 0.230 |
Why?
|
| Pandemics | 6 | 2022 | 1124 | 0.230 |
Why?
|
| Magnetics | 1 | 2005 | 27 | 0.230 |
Why?
|
| Adrenergic Agents | 1 | 2005 | 11 | 0.230 |
Why?
|
| Craving | 4 | 2019 | 13 | 0.230 |
Why?
|
| Paranoid Disorders | 2 | 2002 | 4 | 0.230 |
Why?
|
| Recurrence | 13 | 2019 | 1403 | 0.230 |
Why?
|
| Prefrontal Cortex | 4 | 2020 | 206 | 0.220 |
Why?
|
| Adrenergic alpha-Antagonists | 3 | 2002 | 40 | 0.220 |
Why?
|
| Blood Platelets | 3 | 2004 | 312 | 0.220 |
Why?
|
| Family | 8 | 1991 | 575 | 0.220 |
Why?
|
| Peptides | 2 | 2019 | 824 | 0.220 |
Why?
|
| Mouth | 1 | 2025 | 62 | 0.220 |
Why?
|
| Vaping | 1 | 2024 | 31 | 0.220 |
Why?
|
| Haptens | 2 | 2014 | 6 | 0.220 |
Why?
|
| Corticotropin-Releasing Hormone | 4 | 2016 | 53 | 0.220 |
Why?
|
| Sodium Oxybate | 2 | 2010 | 2 | 0.220 |
Why?
|
| Receptors, Nicotinic | 2 | 2017 | 132 | 0.220 |
Why?
|
| Psychotherapy, Group | 4 | 1998 | 56 | 0.220 |
Why?
|
| Aspirin | 2 | 2003 | 200 | 0.210 |
Why?
|
| Predictive Value of Tests | 6 | 2014 | 2168 | 0.210 |
Why?
|
| Dopamine Antagonists | 2 | 2001 | 37 | 0.210 |
Why?
|
| Circadian Rhythm | 5 | 2010 | 305 | 0.210 |
Why?
|
| Protein Binding | 3 | 2019 | 1663 | 0.210 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2024 | 42 | 0.210 |
Why?
|
| Memory, Short-Term | 4 | 2017 | 141 | 0.210 |
Why?
|
| Natural Language Processing | 1 | 2024 | 70 | 0.210 |
Why?
|
| Interleukin-10 | 2 | 2016 | 179 | 0.200 |
Why?
|
| Excitatory Amino Acid Antagonists | 3 | 2000 | 95 | 0.200 |
Why?
|
| Drug Overdose | 1 | 2024 | 71 | 0.200 |
Why?
|
| Cycloserine | 1 | 2003 | 22 | 0.200 |
Why?
|
| Antimetabolites | 1 | 2003 | 28 | 0.200 |
Why?
|
| Internet | 3 | 2021 | 396 | 0.200 |
Why?
|
| Administration, Oral | 7 | 2019 | 677 | 0.200 |
Why?
|
| Hospitals, Psychiatric | 3 | 2013 | 67 | 0.200 |
Why?
|
| Marriage | 5 | 1991 | 27 | 0.200 |
Why?
|
| Biomarkers | 8 | 2019 | 3130 | 0.200 |
Why?
|
| Benzazepines | 2 | 2012 | 43 | 0.200 |
Why?
|
| Electronic Health Records | 3 | 2024 | 768 | 0.200 |
Why?
|
| Health Policy | 1 | 2005 | 220 | 0.200 |
Why?
|
| Cigarette Smoking | 2 | 2024 | 62 | 0.190 |
Why?
|
| Pituitary-Adrenal System | 3 | 2008 | 38 | 0.190 |
Why?
|
| Attention | 6 | 2013 | 192 | 0.190 |
Why?
|
| Amantadine | 5 | 1995 | 11 | 0.190 |
Why?
|
| Prediabetic State | 1 | 2023 | 65 | 0.190 |
Why?
|
| Hypothalamo-Hypophyseal System | 3 | 2008 | 63 | 0.190 |
Why?
|
| Temporal Lobe | 2 | 2015 | 114 | 0.190 |
Why?
|
| Polyunsaturated Alkamides | 2 | 2018 | 17 | 0.190 |
Why?
|
| Arachidonic Acids | 2 | 2018 | 17 | 0.190 |
Why?
|
| Ketoconazole | 1 | 2002 | 10 | 0.190 |
Why?
|
| Radiopharmaceuticals | 4 | 2004 | 159 | 0.190 |
Why?
|
| Substance Abuse Treatment Centers | 5 | 2012 | 8 | 0.190 |
Why?
|
| Buprenorphine, Naloxone Drug Combination | 1 | 2022 | 5 | 0.190 |
Why?
|
| Antisocial Personality Disorder | 9 | 2006 | 65 | 0.190 |
Why?
|
| Enkephalins | 1 | 2022 | 18 | 0.190 |
Why?
|
| Endocannabinoids | 2 | 2018 | 27 | 0.190 |
Why?
|
| Behavior, Animal | 3 | 2014 | 493 | 0.190 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 764 | 0.190 |
Why?
|
| Reward | 5 | 2012 | 113 | 0.180 |
Why?
|
| Rehabilitation Centers | 1 | 2002 | 27 | 0.180 |
Why?
|
| Social Adjustment | 8 | 2013 | 78 | 0.180 |
Why?
|
| Hospitals, Public | 1 | 2002 | 49 | 0.180 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2021 | 231 | 0.180 |
Why?
|
| Schizophrenia, Paranoid | 7 | 2012 | 11 | 0.180 |
Why?
|
| Receptors, Opioid, delta | 1 | 2021 | 12 | 0.180 |
Why?
|
| Food-Drug Interactions | 1 | 2021 | 10 | 0.180 |
Why?
|
| Premedication | 2 | 2001 | 39 | 0.180 |
Why?
|
| Protein Precursors | 1 | 2022 | 140 | 0.180 |
Why?
|
| Alcoholic Beverages | 1 | 2021 | 17 | 0.180 |
Why?
|
| Social Support | 6 | 2013 | 362 | 0.180 |
Why?
|
| Infusions, Intravenous | 5 | 2008 | 523 | 0.170 |
Why?
|
| Cyclohexanecarboxylic Acids | 2 | 2014 | 17 | 0.170 |
Why?
|
| Health Care Costs | 2 | 2001 | 378 | 0.170 |
Why?
|
| Token Economy | 4 | 2008 | 5 | 0.170 |
Why?
|
| Amines | 2 | 2014 | 36 | 0.170 |
Why?
|
| Cytokines | 2 | 2018 | 1313 | 0.170 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2022 | 96 | 0.170 |
Why?
|
| Research Design | 4 | 2014 | 682 | 0.170 |
Why?
|
| Administration, Inhalation | 1 | 2021 | 184 | 0.170 |
Why?
|
| Motor Activity | 4 | 2014 | 504 | 0.170 |
Why?
|
| Drug Combinations | 3 | 2019 | 264 | 0.170 |
Why?
|
| Rats, Sprague-Dawley | 6 | 2016 | 1132 | 0.170 |
Why?
|
| Piperazines | 3 | 2022 | 243 | 0.170 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2021 | 104 | 0.170 |
Why?
|
| Social Stigma | 1 | 2021 | 78 | 0.170 |
Why?
|
| Personality | 2 | 2017 | 112 | 0.170 |
Why?
|
| Self-Help Groups | 2 | 2013 | 14 | 0.170 |
Why?
|
| Promoter Regions, Genetic | 4 | 2016 | 1208 | 0.170 |
Why?
|
| Locus Coeruleus | 1 | 2020 | 19 | 0.160 |
Why?
|
| Adrenergic alpha-Agonists | 3 | 2009 | 17 | 0.160 |
Why?
|
| Crime | 4 | 1989 | 26 | 0.160 |
Why?
|
| Minisatellite Repeats | 2 | 2019 | 45 | 0.160 |
Why?
|
| Adrenocorticotropic Hormone | 6 | 2010 | 63 | 0.160 |
Why?
|
| Communicable Diseases | 1 | 2022 | 153 | 0.160 |
Why?
|
| Mice, Inbred BALB C | 6 | 2016 | 994 | 0.160 |
Why?
|
| Personality Disorders | 4 | 2005 | 170 | 0.160 |
Why?
|
| AIDS Dementia Complex | 2 | 1997 | 20 | 0.160 |
Why?
|
| Spirituality | 2 | 2013 | 48 | 0.160 |
Why?
|
| Prognosis | 13 | 2013 | 4668 | 0.160 |
Why?
|
| Connecticut | 4 | 2005 | 20 | 0.160 |
Why?
|
| Dissociative Disorders | 1 | 2019 | 12 | 0.160 |
Why?
|
| Microbiota | 1 | 2025 | 426 | 0.160 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 964 | 0.160 |
Why?
|
| Caudate Nucleus | 2 | 2015 | 36 | 0.160 |
Why?
|
| Serum | 2 | 2012 | 43 | 0.160 |
Why?
|
| Immunization, Passive | 1 | 2020 | 120 | 0.160 |
Why?
|
| Homovanillic Acid | 3 | 1998 | 30 | 0.160 |
Why?
|
| Interview, Psychological | 3 | 1990 | 103 | 0.160 |
Why?
|
| Cannabis | 2 | 2018 | 47 | 0.150 |
Why?
|
| Haplotypes | 4 | 2015 | 524 | 0.150 |
Why?
|
| Stress, Physiological | 3 | 2006 | 255 | 0.150 |
Why?
|
| Self Administration | 3 | 2014 | 46 | 0.150 |
Why?
|
| Psychopharmacology | 1 | 2019 | 8 | 0.150 |
Why?
|
| Nimodipine | 1 | 1999 | 5 | 0.150 |
Why?
|
| Brain Ischemia | 2 | 2000 | 249 | 0.150 |
Why?
|
| Rest | 1 | 2019 | 64 | 0.150 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2019 | 40 | 0.150 |
Why?
|
| Interleukin-1beta | 1 | 2019 | 149 | 0.150 |
Why?
|
| Thyrotropin-Releasing Hormone | 2 | 1990 | 9 | 0.150 |
Why?
|
| Biological Availability | 1 | 2019 | 141 | 0.150 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 307 | 0.150 |
Why?
|
| Calcium Channel Blockers | 1 | 1999 | 107 | 0.150 |
Why?
|
| Hospitalization | 7 | 2012 | 1804 | 0.150 |
Why?
|
| Methylphenidate | 2 | 2009 | 55 | 0.150 |
Why?
|
| Polymerase Chain Reaction | 5 | 2013 | 1489 | 0.150 |
Why?
|
| Amidohydrolases | 1 | 2018 | 18 | 0.140 |
Why?
|
| Socioeconomic Factors | 5 | 2013 | 865 | 0.140 |
Why?
|
| Combat Disorders | 3 | 2001 | 22 | 0.140 |
Why?
|
| Absenteeism | 1 | 2018 | 18 | 0.140 |
Why?
|
| Models, Animal | 2 | 2019 | 455 | 0.140 |
Why?
|
| Pyrazoles | 1 | 2001 | 312 | 0.140 |
Why?
|
| Central Nervous System Depressants | 1 | 1998 | 21 | 0.140 |
Why?
|
| Employment | 3 | 1988 | 66 | 0.140 |
Why?
|
| Data Interpretation, Statistical | 3 | 2013 | 220 | 0.140 |
Why?
|
| Evoked Potentials, Auditory | 2 | 2012 | 41 | 0.140 |
Why?
|
| Microglia | 1 | 2019 | 129 | 0.140 |
Why?
|
| Reference Values | 4 | 2010 | 678 | 0.140 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2019 | 138 | 0.140 |
Why?
|
| Peptide T | 1 | 1997 | 1 | 0.140 |
Why?
|
| Mental Health | 1 | 2021 | 361 | 0.140 |
Why?
|
| Quinolones | 2 | 2009 | 56 | 0.140 |
Why?
|
| Mice | 10 | 2025 | 17528 | 0.140 |
Why?
|
| Venoms | 1 | 2018 | 17 | 0.140 |
Why?
|
| Caffeine | 1 | 1998 | 65 | 0.140 |
Why?
|
| Ear | 2 | 1995 | 27 | 0.140 |
Why?
|
| Photic Stimulation | 4 | 2017 | 214 | 0.140 |
Why?
|
| Reflex, Startle | 2 | 2012 | 33 | 0.140 |
Why?
|
| Amphetamines | 2 | 1994 | 9 | 0.140 |
Why?
|
| Methoxyhydroxyphenylglycol | 7 | 2002 | 34 | 0.140 |
Why?
|
| Technetium Tc 99m Exametazime | 3 | 2004 | 8 | 0.140 |
Why?
|
| HIV Seronegativity | 1 | 1997 | 28 | 0.140 |
Why?
|
| Drug Monitoring | 1 | 2019 | 173 | 0.140 |
Why?
|
| Patient Care Team | 2 | 1992 | 546 | 0.140 |
Why?
|
| Cannabinoid Receptor Agonists | 1 | 2017 | 7 | 0.130 |
Why?
|
| Mental Health Services | 1 | 2020 | 257 | 0.130 |
Why?
|
| Enzyme Inhibitors | 4 | 2009 | 563 | 0.130 |
Why?
|
| Serotonin | 5 | 2000 | 203 | 0.130 |
Why?
|
| Behavior | 3 | 2010 | 69 | 0.130 |
Why?
|
| Driving Under the Influence | 1 | 2017 | 1 | 0.130 |
Why?
|
| Educational Status | 3 | 2013 | 274 | 0.130 |
Why?
|
| Vasoconstrictor Agents | 1 | 1998 | 132 | 0.130 |
Why?
|
| Endorphins | 2 | 1987 | 6 | 0.130 |
Why?
|
| Administration, Cutaneous | 3 | 2018 | 65 | 0.130 |
Why?
|
| Epinephrine | 4 | 2005 | 146 | 0.130 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 1738 | 0.130 |
Why?
|
| Public Assistance | 2 | 1987 | 5 | 0.130 |
Why?
|
| Statistics as Topic | 3 | 2013 | 238 | 0.130 |
Why?
|
| Malondialdehyde | 2 | 2007 | 49 | 0.130 |
Why?
|
| Body Mass Index | 5 | 2012 | 1640 | 0.130 |
Why?
|
| Patient Transfer | 1 | 2018 | 107 | 0.130 |
Why?
|
| Reproducibility of Results | 3 | 2007 | 2856 | 0.130 |
Why?
|
| Anti-Anxiety Agents | 3 | 2006 | 71 | 0.130 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2019 | 295 | 0.130 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 1476 | 0.130 |
Why?
|
| Oximes | 3 | 2004 | 53 | 0.130 |
Why?
|
| Dexamethasone | 2 | 1990 | 263 | 0.130 |
Why?
|
| Pemoline | 1 | 1996 | 1 | 0.130 |
Why?
|
| Perindopril | 1 | 2016 | 2 | 0.130 |
Why?
|
| Solute Carrier Family 12, Member 2 | 1 | 2016 | 5 | 0.130 |
Why?
|
| Euphoria | 6 | 2000 | 8 | 0.120 |
Why?
|
| Corticosterone | 3 | 2022 | 55 | 0.120 |
Why?
|
| GTP-Binding Proteins | 1 | 1997 | 159 | 0.120 |
Why?
|
| Inflammation | 2 | 2023 | 1428 | 0.120 |
Why?
|
| Forecasting | 3 | 2007 | 348 | 0.120 |
Why?
|
| Paraventricular Hypothalamic Nucleus | 1 | 2016 | 38 | 0.120 |
Why?
|
| Income | 2 | 1987 | 129 | 0.120 |
Why?
|
| Drug Synergism | 2 | 2015 | 231 | 0.120 |
Why?
|
| Butyrylcholinesterase | 2 | 2012 | 2 | 0.120 |
Why?
|
| National Institute of Mental Health (U.S.) | 1 | 2016 | 13 | 0.120 |
Why?
|
| Social Environment | 4 | 1995 | 117 | 0.120 |
Why?
|
| Mutagenesis, Insertional | 2 | 2013 | 148 | 0.120 |
Why?
|
| Body Temperature | 1 | 1996 | 122 | 0.120 |
Why?
|
| Amino Acid Substitution | 2 | 2016 | 395 | 0.120 |
Why?
|
| Brain Diseases | 1 | 1998 | 280 | 0.120 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2015 | 20 | 0.120 |
Why?
|
| Personality Inventory | 7 | 2001 | 176 | 0.120 |
Why?
|
| Administration, Sublingual | 5 | 2012 | 12 | 0.120 |
Why?
|
| Proportional Hazards Models | 3 | 2010 | 1341 | 0.120 |
Why?
|
| Carbidopa | 2 | 2014 | 17 | 0.120 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2015 | 6 | 0.110 |
Why?
|
| Family Practice | 2 | 2007 | 87 | 0.110 |
Why?
|
| Patient Discharge | 1 | 2019 | 459 | 0.110 |
Why?
|
| Virtual Reality Exposure Therapy | 1 | 2014 | 3 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 359 | 0.110 |
Why?
|
| Autogenic Training | 1 | 1994 | 2 | 0.110 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 454 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 372 | 0.110 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 1991 | 222 | 0.110 |
Why?
|
| Child of Impaired Parents | 2 | 1991 | 19 | 0.110 |
Why?
|
| Levodopa | 2 | 2014 | 94 | 0.110 |
Why?
|
| Thiones | 1 | 2014 | 7 | 0.110 |
Why?
|
| Health Surveys | 3 | 2013 | 245 | 0.110 |
Why?
|
| Saliva | 1 | 2015 | 128 | 0.110 |
Why?
|
| Disease Models, Animal | 5 | 2020 | 4419 | 0.110 |
Why?
|
| Area Under Curve | 5 | 2015 | 293 | 0.110 |
Why?
|
| Receptors, Opioid | 3 | 2002 | 12 | 0.110 |
Why?
|
| Telemedicine | 1 | 2020 | 480 | 0.110 |
Why?
|
| Phenelzine | 2 | 1991 | 4 | 0.110 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2015 | 111 | 0.110 |
Why?
|
| Imipramine | 2 | 1991 | 17 | 0.110 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2016 | 242 | 0.110 |
Why?
|
| Mastication | 1 | 2013 | 6 | 0.100 |
Why?
|
| Rats, Wistar | 2 | 2020 | 306 | 0.100 |
Why?
|
| Sample Size | 1 | 2013 | 83 | 0.100 |
Why?
|
| Electrocardiography | 3 | 2015 | 917 | 0.100 |
Why?
|
| Neurobiology | 2 | 2010 | 26 | 0.100 |
Why?
|
| Phencyclidine Abuse | 2 | 2004 | 2 | 0.100 |
Why?
|
| Retrospective Studies | 7 | 2019 | 16725 | 0.100 |
Why?
|
| Vitamin E | 1 | 2013 | 61 | 0.100 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2013 | 36 | 0.100 |
Why?
|
| White Matter | 1 | 2016 | 205 | 0.100 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2013 | 9 | 0.100 |
Why?
|
| Safety | 1 | 2014 | 210 | 0.100 |
Why?
|
| Alcoholics Anonymous | 1 | 2013 | 3 | 0.100 |
Why?
|
| Russia | 1 | 2013 | 38 | 0.100 |
Why?
|
| Hypnotics and Sedatives | 3 | 2010 | 130 | 0.100 |
Why?
|
| Neuroimaging | 3 | 2021 | 351 | 0.100 |
Why?
|
| Diffusion of Innovation | 2 | 2004 | 79 | 0.100 |
Why?
|
| Length of Stay | 1 | 2019 | 1309 | 0.100 |
Why?
|
| HIV-1 | 1 | 1997 | 469 | 0.100 |
Why?
|
| Free Radicals | 1 | 2013 | 33 | 0.100 |
Why?
|
| Blood Chemical Analysis | 1 | 2013 | 80 | 0.100 |
Why?
|
| Institutionalization | 2 | 2011 | 13 | 0.100 |
Why?
|
| Thyrotropin | 2 | 1990 | 53 | 0.100 |
Why?
|
| Population | 1 | 2012 | 22 | 0.100 |
Why?
|
| S100 Calcium Binding Protein beta Subunit | 2 | 2009 | 16 | 0.100 |
Why?
|
| Religion and Medicine | 1 | 2013 | 25 | 0.100 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2013 | 79 | 0.100 |
Why?
|
| Imidazoles | 1 | 2014 | 210 | 0.100 |
Why?
|
| Diabetes Mellitus | 2 | 2011 | 874 | 0.100 |
Why?
|
| Hallucinogens | 3 | 2018 | 54 | 0.100 |
Why?
|
| Psychometrics | 4 | 2012 | 649 | 0.100 |
Why?
|
| Thyroxine | 3 | 1991 | 62 | 0.100 |
Why?
|
| Precision Medicine | 1 | 2016 | 345 | 0.100 |
Why?
|
| Locomotion | 2 | 2014 | 59 | 0.100 |
Why?
|
| alpha7 Nicotinic Acetylcholine Receptor | 1 | 2012 | 53 | 0.100 |
Why?
|
| Pregnancy Complications | 4 | 2007 | 537 | 0.100 |
Why?
|
| Lipids | 1 | 2016 | 549 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 58 | 0.090 |
Why?
|
| Antibody Affinity | 2 | 2012 | 40 | 0.090 |
Why?
|
| Berberine Alkaloids | 1 | 2011 | 2 | 0.090 |
Why?
|
| Tachycardia, Ventricular | 1 | 2015 | 254 | 0.090 |
Why?
|
| Signal Transduction | 2 | 2019 | 4446 | 0.090 |
Why?
|
| Drug Antagonism | 1 | 1991 | 11 | 0.090 |
Why?
|
| MMPI | 2 | 2017 | 16 | 0.090 |
Why?
|
| Self Efficacy | 1 | 2013 | 196 | 0.090 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2012 | 112 | 0.090 |
Why?
|
| Cation Transport Proteins | 1 | 2012 | 98 | 0.090 |
Why?
|
| Resilience, Psychological | 1 | 2013 | 78 | 0.090 |
Why?
|
| Longitudinal Studies | 4 | 2021 | 1415 | 0.090 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2019 | 788 | 0.090 |
Why?
|
| Administration, Intranasal | 4 | 2001 | 129 | 0.090 |
Why?
|
| Drug and Narcotic Control | 1 | 1991 | 17 | 0.090 |
Why?
|
| Receptor, Serotonin, 5-HT1B | 1 | 2010 | 5 | 0.090 |
Why?
|
| Drugs, Investigational | 1 | 1991 | 25 | 0.090 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2011 | 95 | 0.090 |
Why?
|
| Aripiprazole | 2 | 2009 | 22 | 0.080 |
Why?
|
| Goals | 1 | 2011 | 122 | 0.080 |
Why?
|
| Outpatients | 2 | 2018 | 251 | 0.080 |
Why?
|
| Control Groups | 2 | 2008 | 11 | 0.080 |
Why?
|
| Genetic Variation | 4 | 2012 | 1518 | 0.080 |
Why?
|
| Family Therapy | 3 | 1986 | 34 | 0.080 |
Why?
|
| Data Collection | 2 | 2010 | 368 | 0.080 |
Why?
|
| Oxygen | 4 | 2006 | 544 | 0.080 |
Why?
|
| Health Services Accessibility | 3 | 2005 | 658 | 0.080 |
Why?
|
| Electromyography | 2 | 2015 | 136 | 0.080 |
Why?
|
| Receptors, Neurotransmitter | 1 | 1990 | 20 | 0.080 |
Why?
|
| Long QT Syndrome | 1 | 2011 | 83 | 0.080 |
Why?
|
| Corpus Striatum | 3 | 2017 | 90 | 0.080 |
Why?
|
| Global Health | 1 | 2014 | 604 | 0.080 |
Why?
|
| Monoamine Oxidase | 1 | 2009 | 13 | 0.080 |
Why?
|
| DNA | 2 | 2013 | 1427 | 0.080 |
Why?
|
| Hepatitis B Vaccines | 1 | 2009 | 44 | 0.080 |
Why?
|
| Tobacco Products | 2 | 2024 | 70 | 0.080 |
Why?
|
| Hyperprolactinemia | 1 | 2009 | 23 | 0.080 |
Why?
|
| Gene Deletion | 2 | 2013 | 766 | 0.080 |
Why?
|
| Pueraria | 1 | 2009 | 1 | 0.080 |
Why?
|
| Panax notoginseng | 1 | 2009 | 1 | 0.080 |
Why?
|
| Medicine, African Traditional | 1 | 2009 | 2 | 0.080 |
Why?
|
| Panax | 1 | 2009 | 7 | 0.080 |
Why?
|
| Atomoxetine Hydrochloride | 1 | 2009 | 15 | 0.080 |
Why?
|
| Phenotype | 3 | 2012 | 4295 | 0.080 |
Why?
|
| Chronobiology Disorders | 1 | 2009 | 8 | 0.080 |
Why?
|
| Plants, Medicinal | 1 | 2009 | 25 | 0.070 |
Why?
|
| Radioimmunoassay | 5 | 2009 | 98 | 0.070 |
Why?
|
| Prenatal Care | 1 | 1992 | 357 | 0.070 |
Why?
|
| Interleukin-3 | 1 | 2008 | 17 | 0.070 |
Why?
|
| Polymorphism, Restriction Fragment Length | 3 | 2013 | 137 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 1774 | 0.070 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2008 | 51 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 1023 | 0.070 |
Why?
|
| Immunotoxins | 1 | 2008 | 21 | 0.070 |
Why?
|
| Mental Recall | 1 | 2009 | 136 | 0.070 |
Why?
|
| Self Report | 3 | 2022 | 529 | 0.070 |
Why?
|
| Antigen-Antibody Complex | 1 | 2008 | 59 | 0.070 |
Why?
|
| History, 20th Century | 2 | 2002 | 364 | 0.070 |
Why?
|
| Imagination | 2 | 2006 | 19 | 0.070 |
Why?
|
| Receptors, Interleukin-3 | 1 | 2008 | 4 | 0.070 |
Why?
|
| Logistic Models | 5 | 2012 | 1736 | 0.070 |
Why?
|
| Healthy Volunteers | 2 | 2021 | 148 | 0.070 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2008 | 10 | 0.070 |
Why?
|
| Plant Proteins | 1 | 2009 | 82 | 0.070 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2008 | 41 | 0.070 |
Why?
|
| Receptors, CCR5 | 1 | 2008 | 29 | 0.070 |
Why?
|
| Hospitals, Veterans | 1 | 2010 | 331 | 0.070 |
Why?
|
| Mutation, Missense | 1 | 2012 | 887 | 0.070 |
Why?
|
| Reinforcement Schedule | 1 | 2008 | 4 | 0.070 |
Why?
|
| Neuroleptic Malignant Syndrome | 1 | 1988 | 5 | 0.070 |
Why?
|
| Hepatitis B | 1 | 2009 | 166 | 0.070 |
Why?
|
| Pregnancy | 7 | 2022 | 7391 | 0.070 |
Why?
|
| Nucleus Accumbens | 2 | 2020 | 55 | 0.070 |
Why?
|
| Extinction, Psychological | 1 | 2008 | 25 | 0.070 |
Why?
|
| Counseling | 2 | 2018 | 231 | 0.070 |
Why?
|
| Models, Neurological | 2 | 2014 | 185 | 0.070 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2008 | 33 | 0.070 |
Why?
|
| Lithium | 2 | 1989 | 66 | 0.070 |
Why?
|
| Brain Injuries | 1 | 2013 | 690 | 0.070 |
Why?
|
| Death, Sudden | 1 | 1988 | 44 | 0.070 |
Why?
|
| Patient Admission | 1 | 1989 | 164 | 0.070 |
Why?
|
| Diagnosis, Differential | 9 | 1991 | 1815 | 0.070 |
Why?
|
| Injections, Intravenous | 4 | 2001 | 237 | 0.070 |
Why?
|
| Hypothalamus | 1 | 2009 | 188 | 0.070 |
Why?
|
| Antibodies, Blocking | 1 | 2007 | 57 | 0.070 |
Why?
|
| Sirolimus | 1 | 2009 | 224 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2007 | 87 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2015 | 587 | 0.070 |
Why?
|
| Citalopram | 1 | 2007 | 28 | 0.070 |
Why?
|
| Primary Health Care | 3 | 1998 | 768 | 0.070 |
Why?
|
| Cohort Studies | 4 | 2024 | 4878 | 0.060 |
Why?
|
| Organ Size | 2 | 2020 | 437 | 0.060 |
Why?
|
| Oncogene Protein v-akt | 1 | 2016 | 33 | 0.060 |
Why?
|
| Polyuria | 1 | 1986 | 9 | 0.060 |
Why?
|
| Syndrome | 4 | 2013 | 1113 | 0.060 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 1 | 2007 | 19 | 0.060 |
Why?
|
| Behavioral Symptoms | 1 | 2007 | 25 | 0.060 |
Why?
|
| Catheters, Indwelling | 1 | 2008 | 149 | 0.060 |
Why?
|
| Patient Dropouts | 4 | 1998 | 51 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2010 | 1471 | 0.060 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2000 | 260 | 0.060 |
Why?
|
| Parietal Lobe | 2 | 2015 | 42 | 0.060 |
Why?
|
| Low Back Pain | 1 | 2007 | 39 | 0.060 |
Why?
|
| Synapses | 1 | 1990 | 430 | 0.060 |
Why?
|
| GABA Uptake Inhibitors | 1 | 2006 | 2 | 0.060 |
Why?
|
| Life Change Events | 2 | 1985 | 63 | 0.060 |
Why?
|
| Neurons | 1 | 2016 | 1908 | 0.060 |
Why?
|
| GABA Plasma Membrane Transport Proteins | 1 | 2006 | 9 | 0.060 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2007 | 82 | 0.060 |
Why?
|
| Sampling Studies | 2 | 2004 | 72 | 0.060 |
Why?
|
| Avoidance Learning | 2 | 2017 | 61 | 0.060 |
Why?
|
| Chemoradiotherapy | 1 | 2016 | 114 | 0.060 |
Why?
|
| Electroencephalography | 2 | 2015 | 841 | 0.060 |
Why?
|
| Frontal Lobe | 2 | 2015 | 114 | 0.060 |
Why?
|
| Echo-Planar Imaging | 1 | 2006 | 21 | 0.060 |
Why?
|
| Odds Ratio | 4 | 2014 | 1185 | 0.060 |
Why?
|
| Visual Perception | 1 | 2007 | 124 | 0.060 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2007 | 145 | 0.060 |
Why?
|
| Administration, Intravenous | 2 | 2016 | 165 | 0.060 |
Why?
|
| DNA Methylation | 1 | 2012 | 1034 | 0.060 |
Why?
|
| Propranolol | 1 | 2006 | 110 | 0.060 |
Why?
|
| Social Conditions | 1 | 2005 | 5 | 0.060 |
Why?
|
| Personality Tests | 3 | 1990 | 17 | 0.060 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2005 | 99 | 0.060 |
Why?
|
| Incidence | 4 | 2002 | 3182 | 0.060 |
Why?
|
| Benzhydryl Compounds | 1 | 2006 | 68 | 0.060 |
Why?
|
| Protein Interaction Maps | 1 | 2025 | 91 | 0.060 |
Why?
|
| Mice, Nude | 1 | 2016 | 701 | 0.060 |
Why?
|
| Immunization Schedule | 1 | 2005 | 103 | 0.060 |
Why?
|
| Anxiety Disorders | 4 | 2007 | 695 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 327 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2009 | 641 | 0.060 |
Why?
|
| Tryptophan | 2 | 1995 | 93 | 0.060 |
Why?
|
| Sensitivity and Specificity | 3 | 2003 | 2021 | 0.060 |
Why?
|
| Motor Cortex | 1 | 2005 | 74 | 0.060 |
Why?
|
| Urinalysis | 1 | 2005 | 61 | 0.050 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2006 | 210 | 0.050 |
Why?
|
| Obesity | 2 | 2023 | 2326 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2014 | 339 | 0.050 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2016 | 412 | 0.050 |
Why?
|
| Factor Analysis, Statistical | 1 | 2005 | 230 | 0.050 |
Why?
|
| Random Allocation | 4 | 2017 | 419 | 0.050 |
Why?
|
| Cell Aggregation | 1 | 2004 | 19 | 0.050 |
Why?
|
| Drug-Seeking Behavior | 2 | 2014 | 5 | 0.050 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2004 | 26 | 0.050 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2024 | 56 | 0.050 |
Why?
|
| Celecoxib | 1 | 2023 | 32 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 926 | 0.050 |
Why?
|
| Skull | 1 | 2005 | 147 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2005 | 203 | 0.050 |
Why?
|
| Deep Brain Stimulation | 1 | 2009 | 409 | 0.050 |
Why?
|
| Oxycodone | 1 | 2023 | 14 | 0.050 |
Why?
|
| Regional Blood Flow | 1 | 2004 | 197 | 0.050 |
Why?
|
| Drug Users | 2 | 2016 | 9 | 0.050 |
Why?
|
| Testosterone | 2 | 1991 | 600 | 0.050 |
Why?
|
| Cyclooxygenase 2 | 1 | 2023 | 127 | 0.050 |
Why?
|
| Self-Injurious Behavior | 1 | 2024 | 65 | 0.050 |
Why?
|
| Smokers | 1 | 2023 | 37 | 0.050 |
Why?
|
| Selegiline | 1 | 2003 | 7 | 0.050 |
Why?
|
| Multifactorial Inheritance | 1 | 2024 | 150 | 0.050 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 2003 | 11 | 0.050 |
Why?
|
| Benztropine | 1 | 2022 | 2 | 0.050 |
Why?
|
| Community Health Services | 1 | 2004 | 89 | 0.050 |
Why?
|
| Self Disclosure | 1 | 2003 | 24 | 0.050 |
Why?
|
| Ear, External | 2 | 2000 | 24 | 0.050 |
Why?
|
| Parents | 2 | 1991 | 1068 | 0.050 |
Why?
|
| Thalamus | 2 | 2020 | 77 | 0.050 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2022 | 70 | 0.050 |
Why?
|
| Self Concept | 2 | 2013 | 155 | 0.050 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 1 | 2024 | 128 | 0.050 |
Why?
|
| Kentucky | 1 | 2002 | 27 | 0.050 |
Why?
|
| United States Public Health Service | 1 | 2002 | 5 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 2324 | 0.050 |
Why?
|
| Neuropeptide Y | 3 | 2009 | 34 | 0.050 |
Why?
|
| Pain Measurement | 1 | 2003 | 343 | 0.050 |
Why?
|
| Linear Models | 1 | 2003 | 671 | 0.050 |
Why?
|
| Psychological Tests | 3 | 1989 | 93 | 0.050 |
Why?
|
| Thiazoles | 1 | 2022 | 97 | 0.050 |
Why?
|
| Space Perception | 1 | 2002 | 49 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2007 | 2547 | 0.040 |
Why?
|
| Private Practice | 1 | 2001 | 22 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2024 | 362 | 0.040 |
Why?
|
| Physician's Role | 1 | 2003 | 159 | 0.040 |
Why?
|
| Receptors, Cannabinoid | 1 | 2001 | 7 | 0.040 |
Why?
|
| Receptors, Drug | 1 | 2001 | 27 | 0.040 |
Why?
|
| Fasting | 2 | 2015 | 300 | 0.040 |
Why?
|
| Gender Identity | 1 | 1982 | 72 | 0.040 |
Why?
|
| Putamen | 1 | 2001 | 21 | 0.040 |
Why?
|
| Texas | 2 | 2024 | 3531 | 0.040 |
Why?
|
| Clinical Protocols | 3 | 2012 | 224 | 0.040 |
Why?
|
| Zidovudine | 1 | 2001 | 23 | 0.040 |
Why?
|
| CA3 Region, Hippocampal | 1 | 2021 | 17 | 0.040 |
Why?
|
| Relaxation Therapy | 1 | 2000 | 17 | 0.040 |
Why?
|
| Linkage Disequilibrium | 2 | 2013 | 310 | 0.040 |
Why?
|
| Hemodynamics | 2 | 2010 | 800 | 0.040 |
Why?
|
| Verbal Learning | 1 | 2021 | 68 | 0.040 |
Why?
|
| Universities | 1 | 2021 | 120 | 0.040 |
Why?
|
| Memory | 2 | 2009 | 347 | 0.040 |
Why?
|
| Prospective Studies | 4 | 2022 | 6162 | 0.040 |
Why?
|
| Overweight | 1 | 2023 | 369 | 0.040 |
Why?
|
| Risk-Taking | 2 | 2017 | 95 | 0.040 |
Why?
|
| CA1 Region, Hippocampal | 1 | 2021 | 65 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2021 | 281 | 0.040 |
Why?
|
| Health Services | 1 | 2000 | 66 | 0.040 |
Why?
|
| Syncope | 1 | 2000 | 42 | 0.040 |
Why?
|
| Period Circadian Proteins | 2 | 2010 | 25 | 0.040 |
Why?
|
| Aphrodisiacs | 1 | 1999 | 4 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2002 | 302 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2019 | 59 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2024 | 762 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 3436 | 0.040 |
Why?
|
| Adaptation, Physiological | 2 | 2000 | 257 | 0.040 |
Why?
|
| Neostriatum | 2 | 2015 | 9 | 0.040 |
Why?
|
| Chemoprevention | 1 | 2019 | 51 | 0.040 |
Why?
|
| Limbic System | 1 | 1998 | 21 | 0.040 |
Why?
|
| Social Perception | 2 | 2013 | 53 | 0.040 |
Why?
|
| Comparative Effectiveness Research | 1 | 2019 | 69 | 0.040 |
Why?
|
| Students | 1 | 2021 | 247 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2001 | 526 | 0.040 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2018 | 25 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2024 | 907 | 0.040 |
Why?
|
| Generalization, Stimulus | 1 | 1998 | 1 | 0.040 |
Why?
|
| Mood Disorders | 2 | 1989 | 124 | 0.040 |
Why?
|
| Remission, Spontaneous | 1 | 1998 | 63 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2022 | 603 | 0.040 |
Why?
|
| Intracranial Embolism and Thrombosis | 1 | 1998 | 5 | 0.040 |
Why?
|
| Neurotransmitter Agents | 1 | 1998 | 136 | 0.040 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 1998 | 64 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2025 | 1018 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2020 | 649 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 1998 | 279 | 0.030 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 2017 | 12 | 0.030 |
Why?
|
| Stroop Test | 1 | 2017 | 9 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 1998 | 122 | 0.030 |
Why?
|
| Methyltyrosines | 1 | 1997 | 3 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2004 | 1223 | 0.030 |
Why?
|
| Kinetics | 2 | 2012 | 1089 | 0.030 |
Why?
|
| Urban Health | 1 | 1997 | 74 | 0.030 |
Why?
|
| In Vitro Techniques | 2 | 1997 | 820 | 0.030 |
Why?
|
| Beijing | 1 | 2017 | 2 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2019 | 598 | 0.030 |
Why?
|
| Anti-HIV Agents | 1 | 2001 | 347 | 0.030 |
Why?
|
| Marijuana Smoking | 1 | 2017 | 31 | 0.030 |
Why?
|
| Adenosine Diphosphate Ribose | 1 | 1997 | 7 | 0.030 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 1997 | 12 | 0.030 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 1997 | 19 | 0.030 |
Why?
|
| Aging | 2 | 2003 | 1193 | 0.030 |
Why?
|
| Organotechnetium Compounds | 1 | 1996 | 10 | 0.030 |
Why?
|
| Nerve Degeneration | 1 | 1998 | 127 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2010 | 559 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 282 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2013 | 417 | 0.030 |
Why?
|
| Glutamic Acid | 1 | 1998 | 200 | 0.030 |
Why?
|
| Fingers | 1 | 1997 | 61 | 0.030 |
Why?
|
| Fenfluramine | 1 | 1996 | 12 | 0.030 |
Why?
|
| Blood Glucose | 2 | 2011 | 1083 | 0.030 |
Why?
|
| Grief | 2 | 1987 | 21 | 0.030 |
Why?
|
| GABA-A Receptor Antagonists | 1 | 2016 | 7 | 0.030 |
Why?
|
| Bumetanide | 1 | 2016 | 6 | 0.030 |
Why?
|
| Muscimol | 1 | 2016 | 7 | 0.030 |
Why?
|
| Seizures | 1 | 2021 | 850 | 0.030 |
Why?
|
| GABA-A Receptor Agonists | 1 | 2016 | 6 | 0.030 |
Why?
|
| Pharmacogenomic Variants | 1 | 2016 | 37 | 0.030 |
Why?
|
| Emotions | 2 | 2012 | 355 | 0.030 |
Why?
|
| Sleep | 1 | 2019 | 350 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 200 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 1998 | 235 | 0.030 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2016 | 26 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 1219 | 0.030 |
Why?
|
| Receptors, GABA-A | 1 | 2016 | 58 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2025 | 4495 | 0.030 |
Why?
|
| Pyridazines | 1 | 2016 | 51 | 0.030 |
Why?
|
| Lithium Carbonate | 2 | 1993 | 21 | 0.030 |
Why?
|
| Paranoid Behavior | 1 | 1995 | 1 | 0.030 |
Why?
|
| Functional Neuroimaging | 1 | 2015 | 35 | 0.030 |
Why?
|
| Alpha Rhythm | 1 | 2015 | 9 | 0.030 |
Why?
|
| Morphine Derivatives | 1 | 2014 | 5 | 0.030 |
Why?
|
| Membrane Potentials | 1 | 2016 | 295 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2016 | 199 | 0.030 |
Why?
|
| Stochastic Processes | 1 | 2014 | 34 | 0.030 |
Why?
|
| Iodine Radioisotopes | 3 | 2000 | 71 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2015 | 154 | 0.030 |
Why?
|
| Borderline Personality Disorder | 2 | 1989 | 154 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2015 | 203 | 0.030 |
Why?
|
| Cell Membrane | 1 | 1997 | 447 | 0.030 |
Why?
|
| Cell Degranulation | 1 | 1994 | 26 | 0.030 |
Why?
|
| Complementary Therapies | 1 | 1995 | 40 | 0.030 |
Why?
|
| Lung | 1 | 2022 | 1509 | 0.030 |
Why?
|
| Introns | 1 | 2015 | 281 | 0.030 |
Why?
|
| Risk | 2 | 1987 | 722 | 0.030 |
Why?
|
| Alprazolam | 1 | 1993 | 6 | 0.030 |
Why?
|
| Free Radical Scavengers | 1 | 2013 | 53 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2016 | 827 | 0.030 |
Why?
|
| Learning | 1 | 1997 | 355 | 0.030 |
Why?
|
| Neural Pathways | 1 | 2015 | 260 | 0.030 |
Why?
|
| Protestantism | 1 | 2013 | 3 | 0.030 |
Why?
|
| Epistasis, Genetic | 1 | 2013 | 98 | 0.020 |
Why?
|
| Inactivation, Metabolic | 2 | 1997 | 27 | 0.020 |
Why?
|
| Electroencephalography Phase Synchronization | 1 | 2012 | 3 | 0.020 |
Why?
|
| Afghan Campaign 2001- | 1 | 2013 | 118 | 0.020 |
Why?
|
| Conditioning, Operant | 1 | 2012 | 17 | 0.020 |
Why?
|
| Iraq War, 2003-2011 | 1 | 2013 | 126 | 0.020 |
Why?
|
| Varenicline | 1 | 2012 | 12 | 0.020 |
Why?
|
| Repression, Psychology | 1 | 2012 | 1 | 0.020 |
Why?
|
| Immobilized Proteins | 1 | 2012 | 5 | 0.020 |
Why?
|
| Zinc Transporter 8 | 1 | 2012 | 5 | 0.020 |
Why?
|
| Quinoxalines | 1 | 2012 | 37 | 0.020 |
Why?
|
| Research | 2 | 2004 | 254 | 0.020 |
Why?
|
| Receptors, Dopamine | 1 | 1992 | 30 | 0.020 |
Why?
|
| Surface Plasmon Resonance | 1 | 2012 | 51 | 0.020 |
Why?
|
| Serum Albumin, Bovine | 1 | 2012 | 52 | 0.020 |
Why?
|
| Calorimetry | 1 | 2012 | 63 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2012 | 153 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2012 | 108 | 0.020 |
Why?
|
| Muscle Strength | 1 | 2012 | 79 | 0.020 |
Why?
|
| Blinking | 1 | 2012 | 26 | 0.020 |
Why?
|
| Personality Development | 1 | 1991 | 14 | 0.020 |
Why?
|
| Baclofen | 1 | 1992 | 43 | 0.020 |
Why?
|
| Neonatal Abstinence Syndrome | 1 | 1992 | 19 | 0.020 |
Why?
|
| Guanine | 1 | 2011 | 58 | 0.020 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2012 | 105 | 0.020 |
Why?
|
| Choice Behavior | 1 | 2012 | 132 | 0.020 |
Why?
|
| Health Behavior | 1 | 1994 | 387 | 0.020 |
Why?
|
| Probability | 1 | 1992 | 299 | 0.020 |
Why?
|
| Dependovirus | 1 | 2012 | 143 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 1991 | 102 | 0.020 |
Why?
|
| Neurosciences | 1 | 1991 | 47 | 0.020 |
Why?
|
| Cattle | 1 | 2012 | 535 | 0.020 |
Why?
|
| Immunization | 1 | 2012 | 301 | 0.020 |
Why?
|
| Religion | 1 | 1991 | 44 | 0.020 |
Why?
|
| Genetics, Population | 1 | 2012 | 190 | 0.020 |
Why?
|
| Adenosine | 1 | 2011 | 127 | 0.020 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2012 | 132 | 0.020 |
Why?
|
| Orexins | 1 | 2010 | 9 | 0.020 |
Why?
|
| Patient Selection | 2 | 2009 | 697 | 0.020 |
Why?
|
| Hydroxylation | 1 | 1990 | 50 | 0.020 |
Why?
|
| Glucose Tolerance Test | 1 | 2011 | 199 | 0.020 |
Why?
|
| Fast Foods | 1 | 2010 | 23 | 0.020 |
Why?
|
| Americas | 1 | 2010 | 51 | 0.020 |
Why?
|
| Confusion | 1 | 2010 | 16 | 0.020 |
Why?
|
| Melatonin | 1 | 2010 | 28 | 0.020 |
Why?
|
| Hormones | 1 | 1991 | 167 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2011 | 186 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2012 | 392 | 0.020 |
Why?
|
| Social Class | 1 | 1991 | 197 | 0.020 |
Why?
|
| Respiration | 1 | 2010 | 118 | 0.020 |
Why?
|
| Neuropeptides | 1 | 2010 | 112 | 0.020 |
Why?
|
| Sympathetic Nervous System | 2 | 1987 | 55 | 0.020 |
Why?
|
| Anthropometry | 1 | 2010 | 192 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 1235 | 0.020 |
Why?
|
| Fetal Growth Retardation | 1 | 1992 | 253 | 0.020 |
Why?
|
| Europe | 1 | 2010 | 353 | 0.020 |
Why?
|
| Long-Term Care | 1 | 2009 | 65 | 0.020 |
Why?
|
| Social Problems | 1 | 1989 | 3 | 0.020 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating) | 1 | 2009 | 3 | 0.020 |
Why?
|
| Amphetamine | 1 | 2009 | 13 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 1289 | 0.020 |
Why?
|
| Cotinine | 1 | 2009 | 23 | 0.020 |
Why?
|
| Base Sequence | 1 | 2013 | 2764 | 0.020 |
Why?
|
| CLOCK Proteins | 1 | 2009 | 34 | 0.020 |
Why?
|
| Carbon Monoxide | 1 | 2009 | 24 | 0.020 |
Why?
|
| Neurosecretory Systems | 1 | 2009 | 22 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2012 | 890 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2010 | 349 | 0.020 |
Why?
|
| Criminal Psychology | 1 | 1988 | 3 | 0.020 |
Why?
|
| Family Relations | 1 | 2009 | 67 | 0.020 |
Why?
|
| Consensus | 1 | 2011 | 610 | 0.020 |
Why?
|
| Workplace | 1 | 2009 | 74 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 2009 | 466 | 0.020 |
Why?
|
| Body Temperature Regulation | 1 | 1988 | 50 | 0.020 |
Why?
|
| Neurocognitive Disorders | 1 | 1988 | 74 | 0.020 |
Why?
|
| Manuals as Topic | 1 | 1987 | 10 | 0.020 |
Why?
|
| Anxiety, Separation | 1 | 1987 | 6 | 0.020 |
Why?
|
| Kidney Concentrating Ability | 1 | 1986 | 16 | 0.020 |
Why?
|
| Diabetes Insipidus | 1 | 1986 | 16 | 0.020 |
Why?
|
| Narcissism | 1 | 1986 | 6 | 0.020 |
Why?
|
| Religion and Psychology | 1 | 2007 | 31 | 0.020 |
Why?
|
| Hypokalemia | 1 | 1986 | 40 | 0.020 |
Why?
|
| Hydrochlorothiazide | 1 | 1986 | 62 | 0.020 |
Why?
|
| Psychopathology | 1 | 1986 | 33 | 0.020 |
Why?
|
| Depression, Chemical | 2 | 1997 | 35 | 0.020 |
Why?
|
| Homozygote | 1 | 2008 | 541 | 0.020 |
Why?
|
| Psychotherapy, Brief | 1 | 1986 | 55 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2009 | 665 | 0.010 |
Why?
|
| RNA | 1 | 2009 | 523 | 0.010 |
Why?
|
| Prolactin | 2 | 1997 | 111 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2003 | 6550 | 0.010 |
Why?
|
| Physicians' Offices | 1 | 2004 | 9 | 0.010 |
Why?
|
| Role | 1 | 1984 | 28 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2006 | 742 | 0.010 |
Why?
|
| Housing | 1 | 1983 | 52 | 0.010 |
Why?
|
| Child Development | 1 | 1985 | 265 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2009 | 1207 | 0.010 |
Why?
|
| Attitude to Health | 1 | 1983 | 242 | 0.010 |
Why?
|
| Models, Biological | 1 | 2006 | 1369 | 0.010 |
Why?
|
| Parent-Child Relations | 1 | 1983 | 253 | 0.010 |
Why?
|
| Acoustic Stimulation | 1 | 2001 | 75 | 0.010 |
Why?
|
| Chlorpromazine | 1 | 2000 | 12 | 0.010 |
Why?
|
| Hypertrophy | 1 | 2001 | 101 | 0.010 |
Why?
|
| Pentobarbital | 1 | 2000 | 20 | 0.010 |
Why?
|
| Life Style | 1 | 1984 | 430 | 0.010 |
Why?
|
| Diencephalon | 1 | 2000 | 7 | 0.010 |
Why?
|
| Individuality | 1 | 1999 | 37 | 0.010 |
Why?
|
| Medicare | 1 | 2003 | 418 | 0.010 |
Why?
|
| Brain Stem | 1 | 2000 | 109 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2009 | 2337 | 0.010 |
Why?
|
| Cholinesterases | 1 | 1998 | 6 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1992 | 8362 | 0.010 |
Why?
|
| Drug Hypersensitivity | 1 | 1999 | 97 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 2004 | 655 | 0.010 |
Why?
|
| alpha-Methyltyrosine | 1 | 1997 | 3 | 0.010 |
Why?
|
| Diphenhydramine | 1 | 1997 | 12 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2007 | 3414 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2004 | 879 | 0.010 |
Why?
|
| Sexual Behavior | 1 | 1999 | 238 | 0.010 |
Why?
|
| Health Status | 1 | 1999 | 374 | 0.010 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 1997 | 65 | 0.010 |
Why?
|
| Vasoconstriction | 1 | 1997 | 93 | 0.010 |
Why?
|
| Acute Disease | 1 | 1998 | 1038 | 0.010 |
Why?
|
| Habituation, Psychophysiologic | 1 | 1995 | 13 | 0.010 |
Why?
|
| Drinking | 1 | 1995 | 28 | 0.010 |
Why?
|
| Basal Ganglia | 1 | 1995 | 58 | 0.010 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 1994 | 30 | 0.010 |
Why?
|
| Insufflation | 1 | 1994 | 18 | 0.010 |
Why?
|
| P-Selectin | 1 | 1994 | 68 | 0.010 |
Why?
|
| Platelet Activation | 1 | 1994 | 66 | 0.010 |
Why?
|
| Platelet Aggregation | 1 | 1994 | 107 | 0.010 |
Why?
|
| Panic Disorder | 1 | 1994 | 52 | 0.010 |
Why?
|
| Diazepam | 1 | 1993 | 20 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 1994 | 216 | 0.010 |
Why?
|
| Ischemia | 1 | 1997 | 347 | 0.010 |
Why?
|
| Half-Life | 1 | 1993 | 154 | 0.010 |
Why?
|
| Amino Acids | 1 | 1995 | 612 | 0.010 |
Why?
|
| Growth Hormone | 1 | 1992 | 125 | 0.010 |
Why?
|
| Terminology as Topic | 1 | 1993 | 221 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 1991 | 1348 | 0.000 |
Why?
|
| Adrenal Cortex | 1 | 1987 | 10 | 0.000 |
Why?
|
| Psychiatric Department, Hospital | 1 | 1987 | 23 | 0.000 |
Why?
|
| Evaluation Studies as Topic | 1 | 1987 | 243 | 0.000 |
Why?
|
| Hospitals, University | 1 | 1987 | 100 | 0.000 |
Why?
|
| Chick Embryo | 1 | 1986 | 113 | 0.000 |
Why?
|
| Adrenal Medulla | 1 | 1986 | 8 | 0.000 |
Why?
|
| Affective Symptoms | 1 | 1986 | 56 | 0.000 |
Why?
|
| Drug Tolerance | 1 | 1985 | 38 | 0.000 |
Why?
|